A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

• Sponsor: Sumitomo Pharma Oncology, Inc. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT02467361
• Collaborator: (none)
• Enrollment: 104
• Locations: 8
• Arms: 3
• Duration (Months): 66
• Patients Per Site: 13
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

This is an open label, multi-center, Phase 1/2 study of BBI608 administered in combination with immunotherapy in adult patients with advanced cancers. The goal of the study is to determine the RP2D of BBI608 in combination with each of the immunotherapeutic agents.

Condition or Disease	Intervention/Treatment	Phase
Cancer	Drug: BBI608; Drug: Ipilimumab; Drug: Nivolumab; Drug: Pembrolizumab	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 104 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers
• Study Start Date: Aug 1, 2015
• Actual Primary Completion Date: Jan 29, 2021
• Actual Study Completion Date: Jan 29, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Combo with Ipilimumab	Drug: BBI608; Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.; Other Names: Napabucasin BB608 BBI-608 ; Drug: Ipilimumab; Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.; Other Names: Yervoy
Experimental: Combo with Nivolumab	Drug: BBI608; Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.; Other Names: Napabucasin BB608 BBI-608 ; Drug: Nivolumab; Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.; Other Names: Opdivo
Experimental: Combo with Pembrolizumab	Drug: BBI608; Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.; Other Names: Napabucasin BB608 BBI-608 ; Drug: Pembrolizumab; Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.; Other Names: Keytruda

Outcome Measures

Primary Outcome Measures

1. Determination of the safety and tolerability of BBI608 administered in combination with selected immunotherapeutic agent by assessing dose-limiting toxicities (DLTs) [6 weeks]

2. Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs) [6 weeks]

Secondary Outcome Measures

1. Assessment of the preliminary anti-tumor activity by performing tumor assessments every 8 weeks (Phase 2 portion) [6 months]

   Evaluation of anti-tumor activity will be performed according to Immune Related Response Evaluation Criteria in Solid Tumors (irRECIST).

2. Pharmacokinetic profile of BBI608 administered in combination with the selected immunotherapeutic agent as assessed by maximum plasma concentration and area under the curve [-5min, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 hours on day 1, cycles 1 and 2]

3. Pharmacodynamic activity of BBI608 administered in combination with the selected immunotherapeutic agent as assessed by biomarker analysis [6 months]

   Histopathology and Cancer Stem Cell assays will be performed to provide information of the biomarkers on biopsied patient tumor tissue, and archival samples.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion criteria:

1. Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH) and local regulatory requirements

2. A histologically or cytologically confirmed cancer that is metastatic, unresectable, or recurrent and for which treatment with ipilimumab, or nivolumab, or pembrolizumab is a reasonable therapeutic option in the opinion of the investigator.

3. ≥ 18 years of age

4. Measurable disease as defined by Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST).

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

6. Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last dose

7. Females of childbearing potential must have a negative serum pregnancy test

8. Aspartate transaminase (AST) < 2.5 x upper limit of normal (ULN) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN).

9. Hemoglobin (Hgb) ≥ 9 g/dl

10. Total bilirubin ≤ 1.5 × ULN. Patients with liver lesions who do not have hepatocellular carcinoma and who have a total bilirubin < 2.0 x ULN may be eligible if agreed upon by the investigator and medical monitor for the sponsor.

11. Creatinine ≤ 1.5 × ULN or, for patients with creatinine levels above institutional upper limit of normal, creatinine clearance must be > 60 mL/min/1.73 m^2.

12. Absolute neutrophil count ≥ 1.5 x 10^9/L

13. Platelets ≥ 100 x 10^{9/L; patients with hepatocellular carcinoma may enroll provided they have a platelet count ≥ 75 x 10}9/L.

14. Life expectancy ≥ 3 months

Exclusion criteria:

1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 7 days of first dose of BBI608. Patients may begin BBI608 on a date determined by the investigator and medical monitor for the sponsor after a minimum of 7 days since last receiving anti-cancer treatment, provided that all treatment-related adverse events (AEs) have resolved or have been deemed irreversible

2. Had a surgical procedure requiring general anesthesia or inpatient hospitalization for recovery less than 4 weeks prior to beginning protocol therapy.

3. Any known, untreated, brain metastases. Treated subjects must be stable 4 weeks after completion of treatment for brain metastases and image documented stability is required. Patients must have no clinical symptoms from brain metastases and have not required systemic corticosteroids >10 mg/day prednisone or equivalent for at least 2 weeks prior to first dose of study drug.

4. Pregnant or breastfeeding

5. Unable or unwilling to swallow BBI608 capsules daily

6. Significant gastrointestinal disorder(s) (e.g., active Crohn's disease or ulcerative colitis, or a history of extensive gastric resection and/or small intestinal resection) such that absorption of oral medications is impaired.

7. Has an active autoimmune disease requiring immunosuppression with the exception of subjects with isolated vitiligo, resolved childhood asthma or atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and euthyroid patients with a history of Grave's disease.

8. Has interstitial lung disease or active, non-infectious pneumonitis

9. Has a transplanted organ or has undergone allogeneic bone marrow transplant

10. Has received a live vaccine within 30 days prior to first dose.

11. Known hypersensitivity to a component of protocol therapy

12. Uncontrolled concurrent illness including, but not limited to ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or on mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements

13. Subjects with a history of another primary cancer, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; c) localized prostate cancer not requiring systemic therapy; and c) other primary tumors with no known active disease present that, in the opinion of the investigator and medical monitor for the sponsor, will not affect patient outcome in the setting of the current diagnosis.

14. Abnormal ECGs that are clinically significant such as QT prolongation (QTc > 480 msec), clinically significant cardiac enlargement or hypertrophy, new bundle branch block or existing left bundle branch block, or signs of new, active ischemia.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Colorado Cancer Center	Denver	Colorado	United States	80045
2	Emory University Winship Cancer Institute	Atlanta	Georgia	United States	30322
3	University of Chicago Medicine Comprehensive Cancer Center	Chicago	Illinois	United States	60637
4	Massachusetts General Hospital Cancer Center	Boston	Massachusetts	United States	02114
5	Dana Farber Cancer Institute	Boston	Massachusetts	United States	02215
6	Weill Cornell Medical College	New York	New York	United States	10065
7	Institute for Translational Oncology Research	Greenville	South Carolina	United States	29605
8	MD Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• Sumitomo Pharma Oncology, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Sumitomo Pharma Oncology, Inc.
• ClinicalTrials.gov Identifier: NCT02467361
• Other Study ID Numbers: BBI608-201CIT
• First Posted: Jun 10, 2015
• Last Update Posted: Apr 5, 2022
• Last Verified: Apr 1, 2022

• Keywords provided by Sumitomo Pharma Oncology, Inc.: Neoplasms
• Additional relevant MeSH terms: Pembrolizumab; Nivolumab; Ipilimumab

Study Results

No Results Posted as of Apr 5, 2022